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Abstract
An overview of the main features of cerebral vasospasm is provided in this report, highlighting the
possible future direction of development in the diagnosis and management of this severe complication
of aneurysmal subarachnoid hemorrhage.
Introduction and context
Vasospasm is one of the most dreaded acute complica-
tions, developing 4–15 days after aneurysmal subarach-
noid hemorrhage (SAH). It is characterized by a
pathological, diffuse, and long-lasting narrowing of the
vessel lumen of large-capacity cerebral arteries at the base
of the brain either close or distal to the site of bleeding,
and is associated with a reduced perfusion of the
territories distal to the affected vessel. Angiographic
vasospasm occurs in 30–70% of patients with SAH, but it
leads to clinically evident signs and symptoms in 20–
30% of patients who experience delayed ischemic
neurological deficits. About half of this latter group of
patients suffer severe permanent neurological dysfunc-
tion or death [1].
Vasospasm affects all layers of the involved arterial wall of
the cerebral vessels. A proliferative inflammatory arterio-
pathy is the pathological feature of cerebral vasospasm. In
fact, the adventitia is infiltrated with inflammatory cells
and the neuronal endings are damaged. The media is
thickened and fibrotic, with an increased proliferation of
smoothmuscle cells.The intimashows adisruptionofthe
internal elastic lamina [2].
An important predictor of the occurrence of vasospasm
after SAH is the amount of blood present around the
cerebral arteries of the circle of Willis. The Fisher
computed-tomography rating scale of SAH, and recent
modified versions, have demonstrated a strong clinical
correlation with the development of clinically significant
vasospasm [3–5]. Patients with thick basal cistern blood
and the presence of intraventricular blood in the lateral
ventricles carry the highest risk. Other risk factors include
young age, hypertension, smoking, and cocaine use [6].
It has been clearly demonstrated that prolonged expo-
sure of cerebral arteries to perivascular blood is necessary
for the development of vasospasm. However, it has been
impossible until now to identify a single causative
molecule as the culprit of vasospasm. Nonetheless, there
is evidence that a few agents, such as oxyhemoglobin,
nitric oxide, and endothelin-1, may be contributors to
this pathological event.
Oxyhemoglobin, a product of auto-oxydation of hemo-
globin, can directly or indirectly induce arterial vasocon-
striction, especially if the oxygen-free radical scavenging
systems are insufficient. Oxyhemoglobin can also exert a
scavenging effect toward nitric oxide (a potent vasodi-
lator whose depletion has been demonstrated during
vasospasm) and can stimulate endothelial cells to
produce endothelin-1. Endothelin-1 causes the most
potent and long-lasting vasoconstrictor effect, which is
also associated with morphological changes, mimicking
the delayed cerebral vasospasm. It has been demon-
strated that endothelin-1 levels are increased, not only in
the cerebrospinal fluid during SAH, but also during
severe neuronal injury (when caused independently
from vasospasm or the primary bleeding event).
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neurological symptoms, but are not predictive of
vasospasm as assessed by transcranial Doppler (TCD).
These observations do not exclude a causative role of
endothelin-1 for vasospasm but rather suggest that
endothelin-1 acts as a marker of cerebral ischemic injury
[7–10].
Recent advances
Diagnosis
Angiography of the vessels of the brain is the gold
standard for the diagnosis of cerebral vasospasm.
However, this procedure is invasive, requires the avail-
ability of significant resources, and may cause vessel
dissection or thrombosis. Alternative diagnostic tests,
such as computed tomographic angiography and TCD,
have now been clinically validated [11]. Magnetic
resonance imaging, radionuclide imaging, and electro-
encephalography have also been investigated as diag-
nostic tools.
TCD is not invasive and can be performed at the bedside.
For the middle cerebral artery, TCD has a high specificity
with a threshold value ranging between 160 and
200 cm/s [12]. TCD evaluation is recommended as a
screening tool in high-grade WFNS (World Federation of
Neurological Surgeons) scale patients in whom a
neurological examination cannot be readily followed
to identify those at higher risk [13].
In the most severe cases needing monitoring of
intracranial pressure and cerebral perfusion pressure,
the use of cerebral microdialysis has been proposed to
identify the threshold of anaerobic metabolism
(expressed by the lactate/piruvate ratio as an indirect
sign of hypoperfusion). Cerebral microdialysis in asso-
ciation with other brain-monitoring techniques may
assist in the delivery of targeted therapy for prevention of
secondary ischemic injury [14].
Treatment
Critical care management of patients with aneurysmal
SAH aims at improving neurological outcome, and
includes the treatment of non-neurological systems
affecting the brain; a multi-organ clinical approach
instead of a single-organ approach probably represents
the optimal way to reach this goal. Indeed, recent studies
showed that strategies directed at maintaining nor-
mothermia, normoglycemia, and prevention of anemia
may improve outcome after SAH. In fact, fever, anemia,
and hyperglycemia affect 30–54% of patients with SAH
and are significantly associated with mortality and poor
functional outcome [15].
The specific treatment of cerebral vasospasm aims at
improving cerebral blood flow with one of two possible
approaches: indirect pharmacological protection of the
brain tissue or direct mechanical dilation of the
vasospastic vessel.
Though not proven by any randomized clinical trial,
induced hypertension, hypervolemia, and hemodilution
(triple H therapy) are considered the mainstay of the
treatment of vasospasm. This strategy is associated with a
high rate of complications however, limiting its useful-
ness, and has been demonstrated to be ineffective in
many patients [16]. A recent investigation, focusing on
the effect of each component of triple H therapy on
cerebral blood flow, showed that only vasopressor-
induced elevation of mean arterial pressure caused a
significant increase of regional cerebral blood flow and
brain tissue oxygenation, confirming that cerebral
pressure autoregulation is often impaired in these
patients [17]. Although there is no proven role for
hypervolemia, hypovolemia must be avoided because it
increases the risk of delayed infarction [18]. Regarding
the hemodilution component, recent studies tried to
identify the optimal hemoglobin range and concluded
that extreme hemodilution should be avoided, particu-
larly in patients with a cardiac condition [19].
The calcium channel blocker nimodipine is considered
the standard of care in aneurysmal SAH patients.
Although experimental studies failed to show its ability
to prevent angiographic vasospasm, its administration
immediately after SAH diagnosis and for 10–15 days
thereafter has been shown to improve outcome and
reduce cerebral infarction [20].
Several experimental treatments have recently been
proposed for the management of cerebral vasospasm
(such as, cisternal thrombolysis, surgical removal of the
clot, lipid peroxidation inhibitors, and the use of
scavengers of hydroxyl radicals), but further evidence is
needed to prove their efficacy [21]. Currently, the most
promising experimental treatment is the administration
of magnesium sulfate, statins, nitric oxide donors, or
endothelin-1 antagonists. High-dose magnesium ther-
apy might be efficient as a prophylactic adjacent therapy
after SAH to reduce the risk for poor outcome. Never-
theless, because of the high frequency of side effects,
patients should be observed in an intensive or inter-
mediate care setting and hypomagnesemia should
always be avoided [22].
A meta-analysis based on three small clinical trials
showing reduced incidences of vasospasm, delayed
ischemic deficits, and mortality, advocates the routine
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A phase II clinical trial with an endothelin receptor A
antagonist, clazosentan, has demonstrated a reduction in
the incidence and severity of angiographic vasospasm
from 66 to 23%, while adverse events were comparable
to those of placebo [24]. Moreover, another phase II trial,
testing an antagonist against the endothelin receptors A
and B, showed an improvement in delayed ischemic
deficits, occurring in 30% of patients receiving active
treatment and 37% of patients on placebo [25].
Mechanical dilation of the vasospastic vessel by trans-
luminal cerebral angioplasty has been demonstrated to
effectively reverse radiographically confirmed vasospasm
[26]. Moreover, with this technique, it is possible to
selectively inject vasodilators, such as papaverine and
more recently nicardipine, milrinone, and verapamil
[27]. Nevertheless, since few long-term outcome studies
are available, its superiority to medical management for
symptomatic cerebral vasospasm is questionable [28].
Therefore, the use of angioplasty should be reserved for
patients who failed to improve with conventional
hemodynamic management.
Recently, the effect of prophylactic transluminal balloon
angioplasty on cerebral vasospasm in patients with SAH
(Fisher grade III) has been investigated in a randomized
clinical trial [29]. Fewer patients developed vasospasm
after treatment with angioplasty, and there was a
significant decrease in the need for therapeutic angio-
plasty, however, the use of angioplasty did not improve
the outcome of these patients.
Implications for clinical practice
Although knowledge of the pathophysiology of vasos-
pasm after SAH has advanced significantly over the past
years, it continues to be a major cause of mortality and
morbidity without a known specific treatment.
Recent studies have validated the use of computed-
tomographic angiography and TCD in the diagnosis of
vasospasm, and it has been shown that cerebral
microdialysis in association with other brain-monitoring
techniques may assist in the delivery of targeted therapy
to prevent secondary ischemic injury.
A multi-organ clinical approach to the treatment of
cerebral vasospasm is recommended, including the
maintenance of normothermia, normoglycemia, and
the prevention of anemia.
The efficacy of triple H therapy remains uncertain and its
limitations need to be recognized. Studies into the
administration of magnesium sulfate, statins, nitric
oxide donors, or endothelin-1 antagonists have, how-
ever, proved promising, but further efforts are needed to
translate these results into clinical practice in order to
improve the neurointensive care management of this
severe complication.
Some improvement was seen in preventing vasospasm
using prophylactic transluminal balloon angioplasty,
but the use of angioplasty should be reserved for those
patients who failed to improve with conventional
hemodynamic management.
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